Article in Press
The genesis of most older medicinal agents has generally been empirical. During the past one and a half centuries, at least in the Western countries, discovering and developing drugs has been primarily the domain of pharmaceutical companies largely built upon concepts emerging from organic chemistry. Public sector funding for the discovery of new therapeutics has more recently stimulated local, national, and international groups to band together and focus on new human disease targets and novel treatment approaches. This Perspective describes one contemporary example of a newly formed collaboration that was simulated by a regional drug discovery consortium. University of Virginia, Old Dominion University, and a university spinout company, KeViRx, Inc., partnered under a NIH Small Business Innovation Research grant, to produce potential therapeutics for acute respiratory distress syndrome resulting from the ongoing COVID-19 pandemic.
© 2023 The Authors.
This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND) license.
Original Publication Citation
Lazo, J. S., Colunga Biancatelli, R. M. L., Solopov, P. A., & Catravas, J. D. (2023). An acute respiratory distress syndrome drug development collaboration stimulated by the Virginia Drug Discovery Consortium, SLAS Discovery, 1-6. https://doi.org/10.1016/j.slasd.2023.02.001
Lazo, John S.; Colunga-Biancatelli, Ruben M.L.; Solopov, Pavel A.; and Catravas, John D., "An Acute Respiratory Distress Syndrome Drug Development Collaboration Stimulated by the Virginia Drug Discovery Consortium" (2023). Bioelectrics Publications. 351.
0000-0002-1174-3876 (Colunga Biancatelli), 0000-0002-1705-027X (Solopov), 0000-0002-5098-295X (Catravas)